Citi lowered the firm’s price target on 23andMe to $1.75 from $2.50 and keeps a Neutral rating on the shares post the fiscal Q1 report. The analyst needs to see signposts that 23andMe’s new strategy is bearing fruit before turning more constructive on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ME:
- 23andMe to Report FY2024 First Quarter Financial Results
- 23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
- 23andMe releases Simvastatin Medication Insight report
- 23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
- 23andMe Stock (NASDAQ:ME): Layoffs on the Horizon